Articles tagged
13 articles
ControversyFinance
The Trump family has created a crypto platform called World Liberty Financial, issued a stablecoin ($1), received $500 million from a sovereign fund in the Arab Emirates, and is now applying for a banking license from the federal regulator that his own administration controls. Elizabeth Warren calls it "the largest financial corruption we have ever seen."
ControversyHealth
More than 4,000 Americans have filed lawsuits against the maker of Ozempic alleging they were never given adequate warnings about serious side effects. Cases include vision loss, kidney damage and deaths. And there are lesser-known side effects that scientists are just beginning to study.
ControversyTechnology
On May 1, 2026, the Pentagon made official what had been months in the making: eight of the most powerful technology companies in the world deploy their AI in the United States' highest-class military systems. What that means for the future of civilian technology is a question no one is answering clearly enough.
ControversyTechnology
Microsoft, Meta, DeepL, Oracle. So far in 2026, more than 92,000 technology sector employees have lost their jobs. The official argument in almost all cases is the same: the company needs to "integrate AI at all levels." What no one explains is when the job they promised will arrive.
ControversyTechnology
In February, Anthropic engineers tested their new model and what they saw scared them so much that they decided not to release it to the public. In a few weeks, it found thousands of zero-day vulnerabilities in all operating systems and browsers on the planet, including a flaw that had not been detected for 27 years.
ControversyHealth
The independent French magazine Prescrire publishes every year its list of approved drugs with more risks than benefits. In 2026, it includes antidiabetics, Alzheimer's drugs and decongestants. The question that always raises the list: if they have more risks than benefits, why are they still in the market?
ControversyTechnology
Defense Secretary Pete Hegseth in February applied to Anthropic the same classification typically used for companies with ties to foreign adversaries. Anthropic's crime: refusing to remove safeguards that prevented its AI from being used in mass surveillance and autonomous weapons without human supervision.
ControversyHealth
44% of Spaniards consider the impact of AI on health to be positive. The problem is that many confuse general-purpose generative chatbots with validated clinical systems. The difference between the two can literally be the difference between a correct diagnosis and a damaging one. Osakidetza doctors have issued an urgent warning.
ControversyTechnology
One detail that was buried under the media impact of the Mythos announcement: small, accessible open source models found exactly the same vulnerabilities. Not some. The same ones. What that reveals about the narrative of AI control deserves more attention than it received.
ControversyTechnology
On February 28, 2026, OpenAI announced a landmark contract with the United States Department of Defense. Days later, the company's head of robotics left her position. What happened between those two dates is one of the most revealing stories about the ethical limits of AI in 2026.
ControversyTechnology
On May 7, 2026, the EU agreed to ban AI systems that generate non-consensual sexual deepfakes. Three days later, the US began enforcing its own federal law. Both regulations come years after the technology became widespread and caused real harm to real people.
ControversyHealth
The American HHS canceled funding for mRNA research through BARDA. The FDA rescinded its review of Moderna's mRNA flu vaccine. Researchers warn that political distrust of an already proven technology can delay the first cancer treatments that have been shown to reduce mortality by 49%.
ControversyHealth
Retatrutide does not have regulatory approval in any country. That hasn't stopped people around the world from starting to buy it online in unregulated versions made in China. Doctors are seeing patients appear in consultations who self-medicate with a compound whose complete safety profile is not yet known.